Syneos Health Partners with Medable, Expanding Decentralized Solutions to Bring Clinical Trials Closer to the Patient
Syneos Health and Medable have announced a strategic partnership to enhance decentralized clinical trials, aiming to boost patient access and engagement. This collaboration allows Syneos to utilize Medable's digital platform, which streamlines data collection and minimizes the burden on doctors and patients. The initiative focuses on making clinical trials more inclusive and efficient by deploying real-time data capture technologies. Both companies believe this partnership will transform biopharmaceutical product development and meet the increasing demand for decentralized trials.
- Strategic partnership with Medable to enhance decentralized clinical trials.
- Access to Medable's digital platform to reduce physician burden and improve patient experiences.
- Focus on increasing clinical trial diversity and patient access.
- None.
New Partnership Leverages Medable’s Patient-Centered Cloud Platform, Accelerating Seamless Real-World Data Capture and Fit-for-Purpose Decentralized Solutions
MORRISVILLE, N.C. and PALO ALTO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Medable, the leading cloud platform for patient-centered drug development, today announced a strategic partnership to bring clinical trials closer to the patient. The partnership will deliver new decentralized capabilities to Syneos Health with the aim of increasing clinical trial diversity, while improving patient access and experiences to transform biopharmaceutical product development.
Syneos Health will gain access to Medable’s digital platform that reduces physician burden, simplifies the patient journey, and collects previously difficult to obtain data to speed therapies to patients across the clinical development lifecycle. The collaboration will also deliver a fit-for-purpose decentralized digital solution to Syneos Health customers tailored to the specific attributes and requirements for conducting non-interventional research.
“The demand for decentralized clinical trials has steadily increased as sponsors search for innovative and meaningful ways to drive efficiency, reduce cost and alleviate patient burden,” said Maria Fotiu, Executive Vice President for Decentralized Solutions, Syneos Health. “Our collaboration with Medable will identify opportunities to capture data – real time – to better deliver customized, decentralized solutions. When combined with our Illingworth Research Group mobile research nursing capabilities, we believe we’ll be able to engage more diverse populations and increase access for patients who previously couldn’t participate in clinical trials.”
Decentralized Solutions from Syneos Health combine deep insights, agile technologies and operational excellence to transform clinical trials. Medable’s patient-centered cloud platform is a flexible and modular decentralized clinical trial solution that scales to meet the unique needs of specific therapy areas, indications and protocols. It delivers on-site and at-home access on any web-enabled device utilizing Medable’s foundational TeleVisit, TeleConsent, TeleCOA and remote patient monitoring tools.
“We’re excited to work with Syneos Health to accelerate the shift to patient-centric research,” said Alison Holland, Executive General Manager of Digital and Decentralized Solutions for Medable. “The decentralized model requires industry leaders working closely together across an ecosystem to adopt new tools for decentralized and hybrid studies. Combining Syneos Health’s deep experience with our leading digital platform is a win-win-win for patients, sites and sponsors.”
Medable will also now be part of the Syneos Health Dynamic Assembly® network, an open ecosystem of preferred best-of-breed data and technology collaborators committed to delivering fit-for-purpose solutions designed to strategically address the nuances of each customer engagement.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
About Medable
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.
| Syneos Health Contacts: | ||
| Investor Relations | Press/Media | |
| Ronnie Speight | Gary Gatyas | |
| Senior Vice President, Investor Relations | Executive Director, External Communications | |
| +1 919 745 2745 | +1 908 763 3428 | |
| Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com | |
| Medable Contacts: | ||
| Lisa Barbadora | ||
| Big Valley Marketing for Medable | ||
| +1 (610) 420-3413 | ||
| media@medable.com |
FAQ
What is the purpose of the partnership between Syneos Health and Medable?
How will Medable's platform benefit Syneos Health?
What are the expected outcomes of the collaboration?
When was the partnership between Syneos Health and Medable announced?
What does the partnership mean for clinical trial participants?
